A recently published study explored the impact of 2 different initial doses and a cumulative 2-year dose of rituximab on drug adherence and predictors of adherence to treatment in patients with RA in an observational clinical setting.
Rheumatoid arthritis (RA) is a chronic inflammatory joint disease that affects the lining of joints, causing a painful swelling that can lead to bone erosion. Rituximab, a commonly used therapy in treating RA, is a chimeric monoclonal antibody directed against CD20 surface antigens expressed on pre-B cells and B cells before their differentiation into plasma cells. A recently published study explored the impact of 2 different initial doses and a cumulative 2-year dose of rituximab on drug adherence and predictors of adherence to treatment in patients with RA in an observational clinical setting.
The study found that initial or cumulative 2-year doses of rituximab used for treatment of RA in this observational clinical setting did not significantly influence long-term adherence to treatment, though concomitant methotrexate use and low DAS28, or disease activity score in a count of 28 joints, at baseline predicted better adherence.
All patients with RA starting rituximab treatment between January 2003 and April 2012 at Skane University Hospital in Scania, Sweden were included in the study, and data on patient treatment characteristics were derived from the South Swedish Arthritis Treatment Register. A total of 153 patients, 74.5% female, were included. The mean age and mean disease duration were 60.7 and 15.8 years, respectively. Percentage of rheumatoid factor- (RF) and anti—citrullinated protein antibody- (ACPA) positive patients were 86% and 82% respectively.
Patients received either 500 mg for 2 doses or 1000 mg for 2 doses administered by intravenous infusion on days 1 and 15, pre-medicated with intravenous methylprednisolone. Seventy-four patients (48%) were started on the 500 mg dose and 79 patients (52%) were put on 1000 mg dose. The decision to initiate biologics and the selection of the starting dosage relied on the treating physician’s judgment, as no formal disease activity level was mandatory.
When appropriate, Mann-Whitney and Chi-Square tests were used in order to compare demographic and treatment characteristics between different starting doses. The level of adherence to the prescribed therapy was measured with drug survival using Kaplan-Meier estimates and Cox-regression analysis.
Infection-free survival or time until the infection started was studied using Kaplan-Meir estimates. The possible baseline predictors were determined using Cox-regression analysis. The predictors were chosen based on clinical relevance and included sex, age, and disease duration (per year increase), presence of RF, CRP, DAS28-ESR (or DAS28 measured with erythrocyte sedimentation rate), and Health Assessment Questionnaire (HAQ) scores, concurrent glucocorticoid use, concurrent methotrexate use, and calendar year of treatment initiation (1998 to 2007).
Of the 153 patients, only 42 received the starting dose but not any continuation of treatment. There was no significant difference for drug adherence when comparing starting doses during the first 5 treatment years, also when adjusted for baseline characteristics. The cumulative doses of the drug at 2 years also did not influence drug adherence. Low DAS28 at baseline and methotrexate use were associated with better drug adherence, however.
The optimal dosing for rituximab in RA has been under debated in past years, and the evidence from dose finding studies in RA are still limited. The results of this study are in accordance with previous studies and recent meta-analyses of randomized clinical trials, showing good response to the lower dose and to repeated treatment. However, more information is needed in order to find a definitive optimal dosing amount of RTX for the treatment of RA.
Spanish Real-World Study: Adalimumab Biosimilar MSB11022 Safe, Effective in IBD
May 18th 2024A real-world study in Spain on inflammatory bowel disease (IBD) patients found no meaningful changes in clinical or biochemical markers or differences in effectiveness between the adalimumab originator and the biosimilar MSB11022 (Idacio; Fresenius Kabi) in adalimumab-naïve patients.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Panelists Call for Consistent Education, Support to Improve Patient Comfort With Biosimilars
May 15th 2024At the Festival of Biologics USA, panelists stressed the need for patient-centered communication and education to boost comfort with biosimilars, emphasizing consistent support from health care providers despite restrictive payer policies.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.